Clinicopathologic Characteristics of Patients with Metastatic Colorectal Cancer with Molecular Responses Following Treatment with an Individualized Neoantigen Vaccine Regimen

Chih-Yi (Andy) Liao¹, Benny Johnson², Alexander I. Spira³, David P. Carbone⁴, Brian Henick⁵, Michael Overman², Blasé Polite¹, Sameek Roychowdhury⁴, Amit Mahipal⁶, Daniel Ahn⁷, Melissa Johnson⁸, Desiree Schenk⁹, Kyounghwa Bae⁹, Matthew Davis⁹, Karin Jooss⁹, Andrew R. Ferguson⁹, Benjamin Solomon¹⁰ 1 University of Chicago Comprehensive Cancer Center, Chicago, IL, USA; 2 The University of Texas MD Anderson Cancer Center, Chicago, IL, USA; 3 Virginia, USA; 4 The Ohio State University Medical Center, Columbus, Ohio, USA; 5 Columbia University Medical Center, New York, New York, USA; 6 Mayo Clinic, Rochester, NY, USA; 7 Mayo Clinic, Rochester, NY, USA; 7 Mayo Clinic, Scottsdale, AZ, USA; 8 Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville, Tennessee, USA; 9 Gritstone bio, Inc. Emeryville, California, USA 10 Peter MacCallum Cancer Centre, Melbourne, Australia

Abstract

Background : Individualized neoantigen cancer vaccines aim to benefit patients by generating strong, durable neoantigen-specific CD8 T cells. Previous data showed extended overall survival (OS) in patients with metastatic colorectal cancer (CRC) who achieved a molecular response (MR) versus those who did not after individualized neoantigen vaccination in combination with nivolumab and ipilimumab (Catenacci et al ESMO 2021). We report updated OS and exploratory analysis of clinicopathologic features of patients achieving a MR. Methods: Patients with solid tumors who had received routine chemotherapy were treated in a Phase 1/2 firstin-human study (NCT03639714). The vaccine regimen consisted of sequential administrations of chimpanzee adenovirus and self-amplifying mRNA (samRNA) vectors encoding 20 patient-specific neoantigens in combination with nivolumab (IV 480 mg Q4W) and ipilimumab (SC 30 mg).

Results: Thirteen of 29 patients treated had MSS-CRC. Six of these 13 had stable disease (SD) and 7 had progressive disease (PD) per RECIST v1.1. Six patients achieved a MR defined as \geq -30% reduction in ctDNA. Patients with a MR had prolonged OS compared to patients without a MR (see Table 1). MR was not associated with primary tumor location, liver metastases or KRAS mutations and patients with a MR were not enriched for higher tumor mutation burden (TMB), PD-L1, or T cell inflamed gene expression profiles (GEP) and had similar baseline ctDNA values based on variant allele frequency (VAF) (p-value=0.204) (see Table 1).


	Phase 1: Dose Escalation (N=14)					
	Dose Level 1 N=3	Dose Level 2 N=3	Dose Level 3 N=2	Dose Level N=6		
ChAd	10 ¹² viral					
	particles					
samRNA	30 μg 100 μg		100 μg	300 μg		
lpilimumab (SC)	-	-	30 mg	30 mg		
Nivolumab (IV)	480 mg —					
	Phase 2: Tumor-Specific Expansion Cohorts					

MSS-CRC	

NSCLC GEA

Demographics and Safety

Demographics and Tumor Types	n=29	Safety	
Age: mean (range)	60 (38-77)		Grade 1/
Gender: Female/Male	11/18	Treatment-related adverse	events ≥ 1
Tumor Types		Fever/pyrexia	13
Microsatellite-stable (MSS) Colorectal Cancer	13	Fatigue	10
Median number of prior therapies (range)	2 (2-3)	Injection site pain	8
Gastroesophageal adenocarcinoma (GEA)	13	Diarrhoea	7
Median number of prior therapies (range)	1 (1-2)	Musculoskeletal pain	4
Non-small cell lung cancer	3	Chills	4
Median number of prior therapies (range)	2 (2)	Decreased appetite	4
Prior anti-PD(L)1 therapy	3	Rash	3
No DLTs1 patient discontinued due to a TRAE		* All patients treated with concurrent	-





verall urvival edian in onths)	Primary Tumor Location (# patients)	Presence of liver lesions (# patients)	Median TMB (mutations per megabase, range)	PD-L1 (# patients)	Baseline ctDNA (mean VAF, range)	SD per RECISTv1.1 (# patients)
n: NR o rate:	Colon: 2 Rectum: 3 Both: 1	4	2.9 (2.1-6.6)	<1%: 4 NE: 2	3.2% (0.0–10.1)	5
n: 7.8 o rate: NA	Colon: 5 Rectum: 1 Both: 1	6	3.6 (2.5-17.6)	<1%: 5 NE: 2	7.7% (0.0–17.3)	1

- preliminary observations (NCT05141721, GRANITE-CRC-1L).